Wei AH, Panayiotidis P, Montesinos P, et ashpublications.org
ashpublications.org
— Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive — Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive ...
Blood | Vol 142, Issue 21, Pages (23 November ...ScienceDirect.com
www.sciencedirect.com
— Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy — Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy ...
6-month follow-up of VIALE-C demonstrates improved and ...Nature
www.nature.com
von AH Wei · · Zitiert von: 24 — Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive ... von AH Wei · · Zitiert von: 24 — Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive ...
Alle Infos zum Namen "Wei Ah"
Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow ...ashpublications.org
ashpublications.org
— Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy — Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy ...
A Prospective Phase II Study (VALDAC)ASCO Publications
ascopubs.org
von IS Tiong · · Zitiert von: 2 — Wei AH, Montesinos P, Ivanov V, et al: Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase von IS Tiong · · Zitiert von: 2 — Wei AH, Montesinos P, Ivanov V, et al: Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase
AMLSG - Publications - CTO-IM3cto-im3.de
www.cto-im3.de
... Wei AH, Sierra J, Sanz MA, Brandwein J, de Witte TM, Jansen JH, Niederwieser D, Appelbaum F, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H Wei AH, Sierra J, Sanz MA, Brandwein J, de Witte TM, Jansen JH, Niederwieser D, Appelbaum F, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H ...
Oral Azacitidine (CC-486) for the Treatment of Myeloid ...Clinical Lymphoma, Myeloma and Leukemia
www.clinical-lymphoma-myeloma-leukemia.com
von G Garcia-Manero · · Zitiert von: 16 — 83. Roboz GJ, Ravandi F, Wei AH, et al. CC-486 prolongs survival for patients with Acute Myeloid Leukemia (AML) ... von G Garcia-Manero · · Zitiert von: 16 — 83. Roboz GJ, Ravandi F, Wei AH, et al. CC-486 prolongs survival for patients with Acute Myeloid Leukemia (AML) ...
Publikationen 2022Universitätsklinikum Ulm
www.uniklinik-ulm.de
87. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.Döhner H, Wei AH, Roboz GJ, Montesinos P, Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.Döhner H, Wei AH, Roboz GJ, Montesinos P, ...
subgroup analyses from the phase III QUAZAR AML Europe PMC
europepmc.org
von AH Wei · · Zitiert von: 1 — ... leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial. Wei AH 1 ,. Roboz GJ 2 ,. Dombret H von AH Wei · · Zitiert von: 1 — ... leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial. Wei AH 1 ,. Roboz GJ 2 ,. Dombret H
Paper: Acute Myeloid Leukemia Driven IL- ...The Conference Exchange
ash.confex.com
— Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive — Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive ...
Phase 3 Study Confirms Benefit of Venetoclax/LDAC in ...Targeted Oncology
www.targetedonc.com
— Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase — Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase
AML – Highlights vom EHA-Kongress - Onkologie - Universimed - Medizin...
www.universimed.com
Abstract S1563, EHA 2018, Stockholm 3 Wei AH et al.: Updated safety and efficacy results of phase 1/2 study of venetoclax plus lowdose ...
CAVEAT shows venetoclax plus chemo appropriate for older, fit AML...
www.mdedge.com
Key clinical point: Venetoclax plus attenuated-dose induction chemotherapy may be an option for elderly patients with newly diagnosed AML.Major finding: The...
Venetoclax Granted Breakthrough Therapy Designation by FDA for AML...
www.targetedonc.com
Wei AH, Strickland SA, Roboz GJ, et al. Updated safety and efficacy results of phase 1/2 study of venetoclax plus low-dose cytarabine in ...
Verwandte Suchanfragen zu Wei Ah
|
Personen Vorname "Wei" (618) Name |
sortiert nach Relevanz / Datum